AZNBy Calypso Research7 min read

AstraZeneca (AZN) Q4 2025 Earnings Analysis

Growing Pains at AstraZeneca: $15.5B and a Dose of Reality

Key Takeaways

AstraZeneca (AZN) reported Q4 2025 earnings with revenue of $15.5B, representing a +4.1% year-over-year change. The stock moved +2.7% on earnings day.

The bull case: Broad, high-value late-stage pipeline across oncology, CVRM, respiratory, obesity and amyloidosis, combined with disciplined early-stage BD and global scale, enables AstraZeneca to absorb LOEs, hit its $80bn 2030 ambition, and sustain above-industry growth beyond 2030.

The bear case: Intensifying competition and pricing pressure in obesity and oncology, major CVRM LOEs, rising China/VBP and policy headwinds, and heavy multi-year R&D and CapEx needs could compress returns and make it difficult for AstraZeneca to translate its large pipeline into sustained, high-margin EPS growth.

Financial Highlights

  • Revenue: $15.5B (+4.1% YoY)
  • Gross Profit: $12.4B (79.9% margin, -1.8% YoY)
  • Operating Income: $3.0B (19.2% margin, +5.5% YoY)
  • Net Income: $2.3B
  • TTM Revenue: $58.7B

Stock Performance

  • Earnings Day Move: +2.7%
  • Year-to-Date: +12.2%
  • 1-Year Return: +38.5%
  • vs. S&P 500 (since earnings): +8.6%
  • vs. Nasdaq (since earnings): +11.5%

View live AZN data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from AstraZeneca's Q4 2025 earnings call:

Sustainability of Growth Through 2030 (and Beyond) Given LOEs and $80bn Target

Sentiment: Positive

"We want to be a growth company until 2030, reached this $80 billion ambition, but also be a growth company post 2030. And that is why we need to continue investing in R&D... in technologies, new medicines that will actually change the future of medicines and drive our growth post 2030." — Pascal Soriot
"The $80 billion ambition was on an organic basis, and that does not assume any M&A of any size and scale... a substantial portion [of R&D] is going actually in assets, which won't have any substantial revenue in 2030. So that's all the investment for the beyond 2030 to continue the growth rates because we know in that time frame, there are going to be substantial LOEs." — Aradhana Sarin

2026 Outlook and Ability of BioPharma to Offset Farxiga LOE & China VBP

Sentiment: Positive

"We anticipate total revenue to grow by a mid- to high single-digit percentage, driven by strong underlying momentum in the business... The growth will be delivered despite known headwinds in 2026, including VBP in China... [and] Farxiga will also face loss of exclusivity in the U.S. in April." — Aradhana Sarin
"Yes, we will have a blip for sure regarding the Farxiga LOE but there are enough other growth drivers in order to compensate and potentially to exceed the growth moving forward. So we are quite bullish in our internal forecast regarding the forecast for the biopharma business." — Ruud Dobber

Weight Management / Obesity Strategy and Rationale for Entering a Crowded Market

Sentiment: Mixed

"First of all, I think we truly believe that the market in itself is still quite immature... there's still so much improvement possible in combination therapies and for obesity overweighted people, I think, is very crucial in order to help those patients to reduce their risk of cardiovascular events." — Ruud Dobber
"We would never move a product in Phase III and unleash the kind of spend we have... if we didn't think we have a product with a competitive profile. So I think the short answer to your question is, we believe we have a very competitive profile and it doesn't rely on combinations." — Pascal Soriot

Oncology Growth Durability and Key 2026–27 Catalysts (Imfinzi, Datroway, Enhertu, Calquence, Camizestrant)

Sentiment: Positive

"As we reflect on another strong year of growth, we continue to see sustained momentum in our oncology business heading into 2026... With a clear focus on expanding the reach of our medicines into new markets and with additional indications." — David Fredrickson
"These 6 trials represent only a fraction of the opportunities of our oncology portfolio, which is poised to drive continued growth... reinforcing confidence in our -- in progress on our transformative technologies and therefore, long-term growth prospects through 2030 and beyond." — Susan Galbraith

Camizestrant and Oral SERD Opportunity Post‑lidERA (Adjuvant & Metastatic HR+ Breast)

Sentiment: Positive

"The basis of SERENA-4's confidence is that we have try to design the study to enrich for the endocrine-sensitive components of the first-line setting... So these are clinical features that are enriched -- to enrich for the endocrine-sensitive patient population." — Susan Galbraith
"If you think about CAMBRIA-1, which is in this 2- to 5-year population, that's the prevalent population... It's the broadest program that also allows both that prevalent and incident pool, and it allows us to be in a competitive set of time lines by putting it together in the way that we have." — David Fredrickson

Bull Case

Broad, high-value late-stage pipeline across oncology, CVRM, respiratory, obesity and amyloidosis, combined with disciplined early-stage BD and global scale, enables AstraZeneca to absorb LOEs, hit its $80bn 2030 ambition, and sustain above-industry growth beyond 2030.

Bear Case

Intensifying competition and pricing pressure in obesity and oncology, major CVRM LOEs, rising China/VBP and policy headwinds, and heavy multi-year R&D and CapEx needs could compress returns and make it difficult for AstraZeneca to translate its large pipeline into sustained, high-margin EPS growth.

Looking Ahead

Investors will be closely watching AstraZeneca's next quarterly report for continued execution, particularly around sustainability of Growth Through 2030 (and Beyond) Given LOEs and $80bn Target. With operating margins at 19.2%, margin trends will remain a focal point. The muted stock reaction on earnings day suggests the market is taking a wait-and-see approach, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was AstraZeneca's revenue in Q4 2025?

AstraZeneca reported Q4 2025 revenue of $15.5B, representing a +4.1% year-over-year change.

Did AstraZeneca beat earnings expectations in Q4 2025?

The stock rose +2.7% on earnings day, suggesting the results met or exceeded market expectations. The current bull case centers on: Broad, high-value late-stage pipeline across oncology, CVRM, respiratory, obesity and amyloidosis, combined with disciplined early-stage BD and global scale, enables AstraZeneca to absorb LOEs, hit its $80bn 2030 ambition, and sustain above-industry growth beyond 2030.

What is the bull case for AZN stock?

The bull case for AZN centers on: Broad, high-value late-stage pipeline across oncology, CVRM, respiratory, obesity and amyloidosis, combined with disciplined early-stage BD and global scale, enables AstraZeneca to absorb LOEs, hit its $80bn 2030 ambition, and sustain above-industry growth beyond 2030.

What is the bear case for AZN stock?

The bear case for AZN centers on: Intensifying competition and pricing pressure in obesity and oncology, major CVRM LOEs, rising China/VBP and policy headwinds, and heavy multi-year R&D and CapEx needs could compress returns and make it difficult for AstraZeneca to translate its large pipeline into sustained, high-margin EPS growth.

How has AZN stock performed since its Q4 2025 earnings?

AZN moved +2.7% on the day of its Q4 2025 earnings report, outperforming the S&P 500 by +8.6% since earnings. Year-to-date, the stock has returned +12.2%.

Browse all 400+ earnings reports →

Learn More

Analyze AZN in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for AstraZeneca and 400+ other stocks, explore the full platform.

Open AZN on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.